Inoue Yasuhiro, Miki Chikao, Ojima Eiki, Kobayashi Minako, Hatada Tsuyoshi, Kusunoki Masato
Second Dept. of Surgery, Mie University, School of Medicine.
Gan To Kagaku Ryoho. 2002 Nov;29(11):2009-12.
A 51-year-old man underwent right hemicolectomy due to ascending colon cancer with multiple liver metastases. Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co., Tokyo, Japan, 400 mg/day; and Isovorin, Wyeth Lederle Co., Tokyo Japan, 250 mg/body) was started postoperatively. Two months of modified PMC produced a drastic tumor reduction without any adverse reactions such as diarrhea or myelosuppression observed. At present the patient continues to tolerate the chemotherapy and is being followed as an outpatient clinic. This case suggests the usefulness of modified PMC using Leucovorin for progressive recurrent colon cancer.
一名51岁男性因升结肠癌伴多发肝转移接受了右半结肠切除术。术后开始采用亚叶酸钙进行改良的药代动力学调节化疗(静脉输注5-氟尿嘧啶,600mg/m²/24小时;口服优福定,日本东京大鹏药品工业株式会社,400mg/天;口服甲酰四氢叶酸钙,日本东京惠氏-立达公司,250mg/人)。两个月的改良化疗使肿瘤显著缩小,未观察到腹泻或骨髓抑制等不良反应。目前患者继续耐受化疗,正在门诊随访。该病例提示使用亚叶酸钙的改良化疗对进展性复发性结肠癌有用。